Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701)-Reference-Cited by-同舟云学术

Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701)

Published:2013 Issue:4 Volume:84 Page:233-239
ISSN:1423-0232
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Oki Eiji,Emi Yasunori,Akagi Yoshito,Tokunaga Shoji,Sadanaga Noriaki,Tanaka Takaho,Ogata Yutaka,Saeki Hiroshi,Kakeji Yoshihiro,Baba Hideo,Nishimaki Tadashi,Natsugoe Shoji,Shirouzu Kazuo,Maehara Yoshihiko

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference19 articles.

1. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

2. Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study

3. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

4. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

5. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials;International Journal of Clinical Oncology;2019-07-22

2. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A);International Journal of Clinical Oncology;2019-05-06

3. Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer;American Journal of Clinical Oncology;2018-10

4. Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer;Anticancer Research;2018-01-02

5. Comparison of 627 patients with right- and left-sided colon cancer in China: Differences in clinicopathology, recurrence, and survival;Chronic Diseases and Translational Medicine;2017-03